Key result
Delaying cardioversion for atrial fibrillation >48 hours after onset was associated with an increased risk of composite adverse outcomes.
Why the study?
Does the timing of electrical cardioversion affect the risk of adverse outcomes in patients with atrial fibrillation on oral anticoagulation?
Cohort (n=2,530)
Yes
Does the timing of electrical cardioversion affect the risk of adverse outcomes in patients with atrial fibrillation on oral anticoagulation?
Electrical cardioversion performed 24 to 48 hours after AF onset is associated with the lowest risk of adverse outcomes compared to earlier or later timing.
Answers are grounded in this paper and cite their sources.
May warrant cardioversion within 48 hours in anticoagulated AF; leaves open confirmation in randomized trials.
BACKGROUND: Electrical cardioversion (CV) is essential in rhythm management of atrial fibrillation (AF). However, optimal timing of CV remains unknown. HYPOTHESIS: Timing of CV in AF is associated with risk of adverse events. METHODS: We analyzed the effect of AF episode duration on safety and efficacy of electrical CV in a multicenter, multicohort study exploring 4356 CVs in 2530 patients on oral anticoagulation. The composite adverse outcome included unsuccessful CV, acute arrhythmic complications, thromboembolic events, mortality, and AF recurrence within 30-day follow-up. RESULTS: Study groups were stratified according to duration of index AF episode (<24 h, 24-48 h, 48 h-30d, and > 30d), consisting of 1767, 516, 632, and 1441 CVs, respectively. CVs were unsuccessful in 8.5% (<24 h), 5.4% (24-48 h), 11.1% (48 h-30d), and 13.9% (>30d), respectively (P < 0.01). Occurrence of thromboembolic events (0.1%), mortality (0.1%), and asystole >5 seconds (0.7%) within 30-day follow-up was infrequent and comparable in the study groups. AF recurrence within 30 days after initially successful CVs was 29.8% (<24 h), 26.5% (24-48 h), 37.3% (48 h-30d), and 30.3% (>30d), respectively (P < 0.01). Composite adverse outcome occurred in 1669 (38.4%) CVs, and index AF episode >48 hours was an independent predictor for the composite endpoint (OR: 1.49, 95% CI: 1.28-1.74, P < 0.01) in multivariate analysis. CONCLUSIONS: Optimal timing of CV for AF showed a J-shaped curve, with fewest adverse outcomes in patients with CV performed 24 to 48 hours after onset of AF. In patients with rhythm-control strategy, delaying CV >48 hours is associated with increased risk for adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Hellman et al. (2018) conducted a cohort in Atrial fibrillation (n=2,530). Atrial fibrillation episode duration >48 hours vs. Atrial fibrillation episode duration ≤48 hours was evaluated on Composite adverse outcome (unsuccessful cardioversion, acute arrhythmic complications, thromboembolic events, mortality, and atrial fibrillation recurrence within 30-day follow-up) (OR 1.49, 95% CI 1.28-1.74, p=< 0.01). Delaying cardioversion for atrial fibrillation >48 hours after onset was associated with an increased risk of composite adverse outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: